CVX
32
4
VNO
59
2
PRGO
37
2
MET
66
5
PYPL
70
2
GRMN
59
3
EQT
50
5
MAR
66
4
URI
59
3
MRK
48
2
HES
44
4
EIX
45
2
FRT
50
2
NWS
54
-6
IRM
52
2
NUE
47
3
DOW
18
3
WFC
77
3
FAST
56
4
D
43
-2
CVX
32
4
VNO
59
2
PRGO
37
2
MET
66
5
PYPL
70
2
GRMN
59
3
EQT
50
5
MAR
66
4
URI
59
3
MRK
48
2
HES
44
4
EIX
45
2
FRT
50
2
NWS
54
-6
IRM
52
2
NUE
47
3
DOW
18
3
WFC
77
3
FAST
56
4
D
43
-2
Financhill
Back

Intellia Therapeutics 10K Form

Sell
24

NTLA
Intellia Therapeutics

Last Price:
$8.06
Seasonality Move:
22.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $57.9M
Cash Flow: $-149.7M
Price / Cash Flow: 0
Annual Sales: $7.53
Price / Book: 1.07

Profitability

EPS (TTM): -5.23000
Net Income (TTM): $-525.9M
Gross Margin: --
Return on Equity: -56.9%
Return on Assets: -45.33%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 805.69% of Revenue.
  • The Net Earning history of NTLA is -896.77% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 2 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.9
Quick Ratio: 4.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
24
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?